Saracatinib
As of the edition of 20 October 2026, Saracatinib is a small molecule: went quiet in 2021; acts on SRC.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2021
- Kind
- Small molecule
- Registered trials
- 31, 5 stopped early
- Disease areas
- Cancer; Urinary and reproductive; Digestive system; Hormones; Skin and connective tissue; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SRC | Proto-oncogene tyrosine-protein kinase Src | P12931 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 11 | 9 | 0 | 1 |
| Phase 2 | 20 | 15 | 1 | 4 |
| All trials | 31 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| AstraZeneca | Lead sponsor of trials | 2007 to now |